CRL News and Press, Charles River Laboratories International Inc. From 06/17/24

Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector productio...

2024-06-11 19:39:16 ET Summary Ariel Investments' 13F portfolio value increased to $10.17B this quarter, with around 150 positions. New stakes include Aptiv PLC, while stake increases were seen in Mattel, Inc., Sphere Entertainment, and others. Stake decreases were observed in...

Project will utilize an integrated approach to develop an in vitro alternative to inhalation toxicology studies Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multidisciplinary program, funded through a $1.3 million grant from the Foundation for Chemistry R...

2024-06-07 13:11:42 ET More on Charles River Laboratories Charles River Laboratories: Fair Valuation Against Fundamentals Charles River Laboratories International, Inc. (CRL) Q1 2024 Earnings Call Transcript Charles River Laboratories Q1 2024 Earnings Preview ...

New turnkey research facility will provide AAALAC-accredited flexible vivarium space for Massachusetts biopharmaceutical hub Charles River Laboratories International, Inc. (NYSE: CRL) has announced the opening of a new Charles River Accelerator and Development Lab (CRADL ® ) fa...

2024-06-04 16:12:36 ET Summary Medpace Holdings is a US-based clinical research organization that is well-positioned to benefit from increased demand due to geopolitical risks affecting Chinese firms. Medpace stands out among its peers due to its growth orientation, competitive ma...

Through ongoing collaboration with Sanofi, Charles River will explore use of Virtual Control Groups in nonclinical toxicology Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies a...

2024-05-31 04:44:45 ET Summary The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratories is a promising investment in this industry, with...

Fast Track and Modular frameworks facilitate product development continuity via seamless process transfer to the Company’s viral vector Center of Excellence Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track v...

2024-05-09 19:00:06 ET Elizabeth Anderson from Evercore ISI issued a price target of $265.00 for CRL on 2024-05-09 16:15:00. The adjusted price target was set to $265.00. At the time of the announcement, CRL was trading at $230.09. The overall price target consensus is a...